Related Experiment Video
Updated: Jul 3, 2026

Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals
Published on: September 20, 2021
[Experimental study of suppression of reactivation of herpes simplex virus type 1 by cyclooxygenase 2 inhibitor with
Yuan Xia1, Zhen-Ping Huang, Fei Ma
1Department of Ophthalmology, Nanfing General Hospital of Nanjing Military Command, PMA, Nanjing 210002, China. linda_xia@21cn.com
Objective:
To study whether the cyclooxygenase 2 (COX-2) inhibitor can block the herpes virus reactivation and whether the combination of COX-2 inhibitor with acyclovir can enhance the inhibition of virus reactivation.
Methods:
It was a experimental study. Mice were randomly divided into six groups. Five groups were HSV-1 infected mice, which included: group A, treated with lornoxicam and acyclovir; groups B and C, treated with lornoxicam or acyclovir, respectively; groups E and F were injected with saline as the untreated control groups. The sixth group was uninfected mice as the control group. All groups were undergone to reactivate the herpes virus by UV-B except group F. The shedding of the virus was determined by cultures of ocular swab or ganglion homogenates with indicator cells.
Results:
The rates of corneas and ganglia containing the infectious virus in the groups A, B and C were significantly lower than those in the control group D, (cornea: 2XA-D = 36.88, XB-D = 22.43, X2C-D = 20.32, P < 0.05, ganglia : X2A-D = 49.91 X2B-D =29. 16,X2C.D = 24.89, P < 0.05). Combined use of these two drugs in group A showed no significant statistical difference as compared with using them separately in the cornea culture (X2A-B= 2.75, X2A-C = 3.66, 0. 05 < P < 0.1), but there was significant difference in trigeminal ganglia culture (X2A-B = 4.78, 2XA-c = 6. 97, P < 0.05).
Conclusions:
These experiments demonstrate that a selective COX-2 inhibitor can suppress UV-B-induced herpes virus reactivation in the cornea and nervous system. A combination of acyclovir does not significantly enhance the inhibition of virus reactivation by lornoxicam. These results provide a new method to prevent the recurrence of HSK.
Insights
A selective cyclooxygenase 2 (COX-2) inhibitor suppresses herpes virus reactivation. Combining this inhibitor with acyclovir did not significantly improve results for herpes virus reactivation, offering a new prevention method for herpetic simplex keratitis (HSK).
Area of Science:
- Virology
- Immunology
- Pharmacology
Context:
- Herpes Simplex Virus type 1 (HSV-1) reactivation can cause significant ocular morbidity, such as herpetic simplex keratitis (HSK).
- UV-B radiation is a known trigger for HSV-1 reactivation.
- Current treatments for HSV-1 reactivation often involve antiviral medications like acyclovir.
Purpose:
- To investigate the efficacy of a selective cyclooxygenase 2 (COX-2) inhibitor, lornoxicam, in blocking UV-B-induced herpes virus reactivation.
- To determine if combining lornoxicam with acyclovir enhances the inhibition of herpes virus reactivation compared to monotherapy.
Summary:
- An experimental study in mice demonstrated that lornoxicam significantly suppressed HSV-1 reactivation in both the cornea and trigeminal ganglia after UV-B exposure.
- While both lornoxicam and acyclovir monotherapy reduced viral shedding, their combination did not show a statistically significant enhancement in inhibiting reactivation in the cornea.
- However, the combination therapy showed a significant benefit in suppressing viral reactivation within the trigeminal ganglia compared to lornoxicam alone.
Impact:
- These findings suggest that selective COX-2 inhibitors represent a potential therapeutic strategy for preventing herpes virus reactivation.
- The study provides a novel approach for managing and preventing recurrent herpetic simplex keratitis (HSK).
- Further research may explore optimizing combination therapies for enhanced efficacy in specific anatomical sites.
Related Concept Videos
Herpes
Antiviral Nucleoside Inhibitors
Genital Herpes
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis

